This article discusses the molecular pharmacology of trace amine-associated receptor 1 (TAAR1) and its potential role in advancing antipsychotic drug discovery. Schizophrenia, a chronic mental disorder, is characterized by negative symptoms, positive symptoms, and cognitive impairment. Current antipsychotic drugs have limited efficacy and are associated with side effects. TAAR1 has emerged as a potential therapeutic target for psychiatric disorders, and recent studies have provided insights into the molecular mechanisms and activation characteristics of TAAR1. These findings could contribute to the development of new antipsychotic drugs. [Extracted from the article]